Scholarlink

<p>Cancer-associated thrombosis (CAT) is the second leading cause of death in cancer patients, with venous thromboembolism affecting 20–30% of cases. While conventional models emphasize biochemical mediators such as tissue factor (TF) and inflammatory cytokines, they incompletely explain the spatial heterogeneity and therapeutic resistance of CAT. This review presents a mechanobiology-centered framework that integrates physical forces—including aberrant hemodynamics, elevated interstitial pressure, and matrix stiffening—with cellular mechanotransduction to explain thrombogenesis in malignancy. We examine how tumor-induced mechanical cues activate PIEZO1 channels, integrin-focal adhesion signaling, and YAP/TAZ transcriptional programs, collectively driving TF expression, extracellular vesicle release, platelet hyperreactivity, and neutrophil extracellular trap formation. Red blood cells (RBCs) emerge as underappreciated mechanobiological contributors through rheology-dependent and phosphatidylserine-mediated mechanisms. Advanced microfluidic platforms recapitulating tumor-specific shear conditions enable mechanistic dissection and compound screening under physiologically relevant flow. Therapeutic strategies targeting upstream mechanosensitive pathways—including PIEZO1 modulation, YAP/TAZ-TEAD inhibition, and membrane tension control—offer potential to attenuate prothrombotic outputs while preserving hemostasis. Integration of mechanobiological biomarkers with machine-learning risk models may enhance CAT prediction beyond current clinical scores. This multi-scale perspective bridges molecular mechanosensors to tissue-level hemodynamics, establishing a foundation for precision thromboprophylaxis informed by the mechanical phenotype of individual tumors.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanobiology of cancer-associated thrombosis: from molecular mechanisms to therapeutic innovation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月18日

查看全文
  • Zilin Tonya Wang,
  • Yixuan Ria Hu,
  • Zilong Zhan,
  • Alexander Dupuy,
  • Zhian Yao,
  • Xuyu Liu,
  • Lining Arnold Ju

摘要

Cancer-associated thrombosis (CAT) is the second leading cause of death in cancer patients, with venous thromboembolism affecting 20–30% of cases. While conventional models emphasize biochemical mediators such as tissue factor (TF) and inflammatory cytokines, they incompletely explain the spatial heterogeneity and therapeutic resistance of CAT. This review presents a mechanobiology-centered framework that integrates physical forces—including aberrant hemodynamics, elevated interstitial pressure, and matrix stiffening—with cellular mechanotransduction to explain thrombogenesis in malignancy. We examine how tumor-induced mechanical cues activate PIEZO1 channels, integrin-focal adhesion signaling, and YAP/TAZ transcriptional programs, collectively driving TF expression, extracellular vesicle release, platelet hyperreactivity, and neutrophil extracellular trap formation. Red blood cells (RBCs) emerge as underappreciated mechanobiological contributors through rheology-dependent and phosphatidylserine-mediated mechanisms. Advanced microfluidic platforms recapitulating tumor-specific shear conditions enable mechanistic dissection and compound screening under physiologically relevant flow. Therapeutic strategies targeting upstream mechanosensitive pathways—including PIEZO1 modulation, YAP/TAZ-TEAD inhibition, and membrane tension control—offer potential to attenuate prothrombotic outputs while preserving hemostasis. Integration of mechanobiological biomarkers with machine-learning risk models may enhance CAT prediction beyond current clinical scores. This multi-scale perspective bridges molecular mechanosensors to tissue-level hemodynamics, establishing a foundation for precision thromboprophylaxis informed by the mechanical phenotype of individual tumors.

Graphical Abstract